EpiDestiny

Novo Nordisk acquired its pyruvate kinase-R (PKR) activator etavopivat when it bought Forma Therapeutics for $1.1bn to expand its portfolio in rare hemoglobinopathies outside of hemophilia. At the Ame

Novo Nordisk A/S has been working to diversify outside of its core therapeutic areas in diabetes and obesity and announced on 1 September an agreement to buy Forma Therapeutics Inc. to forward that

Novo Nordisk AS showed its interest in acquiring external research assets by its failed bid for Ablynx NV and that company's blood disorders lead program, earlier this year and, subsequently, the D

Novo Nordisk AS struggled in the first quarter of 2018 to gain traction from its insulin-based products - as US pricing pressure in diabetes continues to mount - but its GLP-1 products appeared insul